Lenger ut i 49 omtales den planlagte studien uten at jeg fikk med meg studieoppsettet siden det allerede var gått ut på dato. Hell i uhell betegnet Wiklund det at nyheten kom da og ikke ett år senere. Det ville ha blitt dyrt.
Enig i at Targo er sterkt undervurdert men det kan ikke vi to gjøre noe med. Er bare å vente siden jeg har nok.
1 Like
Skal vi gjløre noe for å få Targo mer frem i lyset bør vi begynne å skrive på en Targotråd. Vet ikke om @Fornybar så koblingen da han benyttet denne tråden.
Tg01 gikk i opererte pankreaskreftpasienter, mens denne går i chemonaive pasienter med spredning av kreften. Jeg anså det ikke som så relevant for TG01 at den passet bedre inn der enn her.
1 Like
Noen som har tilgang til denne?
1 Like
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00404-6/fulltext#
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial
At database lock (March 8, 2020), with a median follow-up of 21·9 months (IQR 17·7–28·5), overall survival was longer in the ramucirumab group (HR 0·71, 70% CI 0·59–0·85; p=0·028). Median overall survival was 13·8 months (70% CI 12·7–14·4) in the gemcitabine plus ramucirumab group and 7·5 months (6·9–8·9) in the gemcitabine plus placebo group.
Meget interessant med boblende nanoteknolologi mot skader ved cellegiftbehandling fra NTNU/SINTEF:
1 Like
https://www.annalsofoncology.org/article/S0923-7534(21)04417-3/fulltext
# LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651
TIGIT-hemmere begynner å vise effekt.
1 Like
Rett etter LAG3-hemming viste litt effekt med Opdivo får TIGIT-hemmeren til Genentech seg et slag over nesen.
Tiragolumab is a novel immune checkpoint inhibitor with an intact Fc region. Tiragolumab selectively binds to TIGIT, a novel inhibitory immune checkpoint, which suppresses the immune response to cancer. Based on preclinical research, tiragolumab is thought to work as an immune amplifier with other cancer immunotherapies such as Tecentriq® (atezolizumab). The TIGIT pathway is distinct but complementary to the PD-L1/PD-1 pathway. Dual blockade with tiragolumab and Tecentriq may help overcome immune suppression and restore the immune response.
2 Likes
https://www.nature.com/articles/s43018-022-00362-5
Further analysis revealed that intratumoral neoantigen-specific CD8+ T cells expressed negative regulators of T cell function, including PD-1 as well as the transcription factor TOX. These features are associated with CD8+ T cells that lack effector function and are designated as dysfunctional or exhausted T cells (Td/ex)13. At the same time, other immune cells within the tumor microenvironment (TME) expressed high levels of PD-L1. Therefore, Liu et al.14 assessed whether ICT antibody blockade of PD-1–PD-L1 interaction in the TME could enhance the efficacy of the neoantigen vaccine. Whereas monotherapy via either neoantigen vaccination or anti-PD-L1 treatment slowed tumor outgrowth, combining neoantigen vaccination and anti-PD-L1 provided superior efficacy and led to complete tumor rejection (Fig. 1a).
1 Like
1 Like